Crossmark

Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer

Crossref DOI link: https://doi.org/10.1186/s13046-018-0999-5

Published Online: 2019-01-11

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Reguera-Nuñez, Elaine

Xu, Ping

Chow, Annabelle

Man, Shan

Hilberg, Frank

Kerbel, Robert S.
Funding

Funding for this research was provided by:

Canadian Institutes of Health Research

Sponsored Research Agreement from Boehringer Ingelheim RCV, Vienna, Austria
License Information

Text and Data Mining valid from 2019-01-11
More Information

Article History

Received: 29 August 2018

Accepted: 6 December 2018

First Online: 11 January 2019

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: FH works for Boehringer Ingelheim RCV, Vienna, Austria. The other authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below